Innovent Biologics, Inc.
1801
株式のランク
#1164
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou,... Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
株価
$11.40
時価総額
$19.88B
変化（1日）
1.95%
変化（1年）
1.94%
国
CN
取引 Innovent Biologics, Inc. (1801)
カテゴリー
Healthcare
Innovent Biologics, Inc.（1801）のP/E比率
October 2026 時点のP/E比率 TTM 105.41
Innovent Biologics, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は 105.41 です。2023 年末時点での P/E は -58.77 でした。
Innovent Biologics, Inc. の P/E 比率の履歴（2016 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 105.41 | -117.83% |
| 2024 | -591.18 | 905.86% |
| 2023 | -58.77 | 190.58% |
| 2022 | -20.23 | -3.23% |
| 2021 | -20.90 | -77.80% |
| 2020 | -94.13 | 479.66% |
| 2019 | -16.24 | 1,224.06% |
| 2018 | -1.23 | -95.53% |
| 2017 | -27.44 | -16.62% |
| 2016 | -32.91 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 28.78 | -72.70% |
US
|
|
| -28.36 | -126.90% |
US
|
|
| -24.57 | -123.31% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -71.23% |
NL
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。